The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Lauren (Hansen) Holznienkemper is a lead editor for the small business vertical at Forbes Advisor, specializing in HR, payroll and recruiting solutions for small businesses. Using research and writing ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Threat actors have been exploiting a command injection vulnerability in Array AG Series VPN devices to plant webshells and create rogue users. Array Networks fixed the vulnerability in a May security ...

Question: “We are a married couple with return-to-office mandates. This leads to a number of issues as our home address is in Illinois but our working address is in North Carolina. We’re renting in ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

The Trump administration offered states a deal: pledge to enact White House-favored policies for a chance to win a bigger share of the $50 billion aimed at transforming the nation’s struggling rural ...

President Trump is shifting from discussion of the long-lasting competition among the world’s biggest economies and nuclear powers. By David E. Sanger David E. Sanger has covered five American ...